REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Gut Repair Stack

Recovery & Healingbeginner

85

synergy

85
Share
Peptides

2

Avg Daily mcg

1,000

Level

beginner

Added

May 17, 2026

Overview

The Gut Repair Stack targets the gastrointestinal system specifically, combining BPC-157''s mucosal healing properties with KPV''s potent anti-inflammatory action in the gut lining. This combination has become a go-to protocol for functional medicine practitioners working with IBS, Crohn''s disease, ulcerative colitis, SIBO, post-antibiotic gut damage, and leaky gut syndrome. BPC-157 was originally isolated from human gastric juice and was first studied for its effects on the gastrointestinal system. It promotes healing of the gut mucosa through multiple mechanisms: stimulating cell migration to damaged mucosal surfaces, increasing blood flow to the GI tract, and upregulating growth factor expression in intestinal tissue. Both oral and subcutaneous administration are used — oral BPC-157 is increasingly studied for direct GI application. KPV (Lys-Pro-Val) is a tripeptide fragment of alpha-MSH with direct anti-inflammatory effects in the gut. It targets NF-κB signaling, one of the primary inflammatory pathways driving IBD, Crohn''s, and colitis. Unlike systemic anti-inflammatory drugs, KPV acts preferentially in mucosal tissue and can cross the intestinal epithelium to reach submucosal immune cells. It also demonstrates antimicrobial properties that may support a healthier gut microbiome. Together, BPC-157 rebuilds the gut architecture while KPV quiets the immune over-activation that prevents healing. This is particularly powerful in chronic inflammatory gut conditions where the inflammatory environment actively disrupts mucosal repair. Users typically take KPV orally (capsule or liquid) and BPC-157 orally or subcutaneously depending on the condition being targeted.

Dosing Protocol

BPC-157

Twice per day· oral or subcutaneous

Read more about BPC-157 →

250 mcg

per dose

KPV

Every day· oral

Read more about KPV →

500 mcg

per dose

Goals & Evidence

Gut healingIBS reliefLeaky gutIntestinal inflammationIBD support
Evidence tier:Animal Studies

Warnings

  • Oral BPC-157 has less bioavailability data than injectable. KPV is currently FDA Category 2.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.